NTRK1 and psoriasis: HSP90 client proteins, such as receptor tyrosine kinases JAK1/2 (involved in uncontrolled proliferation), AKT (angiogenesis), and IL‐6 (inflammation), play diverse roles in pathogenesis.[43] Therefore, pronounced expression of HSP90 has been detected in almost all classes of cancers as well as benign proliferation like psoriasis.[44] Several HSP90 inhibitors have been developed to in treating cancer and plaque‐type psoriasis but none of them have yet been approved due to different drawbacks.